NCT03933163 is a Phase 2 clinical trial of Resveratrol in Friedreich Ataxia, sponsored by Murdoch Childrens Research Institute.

Who is sponsoring NCT03933163?

NCT03933163 is sponsored by Murdoch Childrens Research Institute.

What drugs are being tested in NCT03933163?

Interventions in NCT03933163: Resveratrol.

What condition does NCT03933163 study?

NCT03933163 studies Friedreich Ataxia.

Is NCT03933163 still recruiting?

NCT03933163 is currently completed. Last updated 22 May 2024.

Last reviewed 2024-05-22 · How we verify

NCT03933163

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Micronised Resveratrol as a Treatment for Friedreich Ataxia

Completed Phase 2 Last updated 22 May 2024

What this trial tests

Phase 2 trial testing Resveratrol in Friedreich Ataxia in 25 participants. Completed in 28 March 2024.

Timeline

23 May 2019

Primary endpoint
28 March 2024

28 March 2024

Quick facts

Lead sponsor	Murdoch Childrens Research Institute
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	25
Start date	23 May 2019
Primary completion	28 March 2024
Estimated completion	28 March 2024
Sites	4 locations across Australia

Drugs / interventions tested

Resveratrol — full drug profile →

Conditions studied

Friedreich Ataxia — all drugs for Friedreich Ataxia →

Sponsor

Murdoch Childrens Research Institute

Who can join

16 and older, any sex, with Friedreich Ataxia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to assess the efficacy of micronised resveratrol as a treatment for FRDA, in terms of reducing the severity of ataxia symptoms at 24 weeks, through a randomised blinded, placebo controlled crossover trial.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting oxidative stress in disease: promise and limitations of antioxidant therapy.
Forman HJ, Zhang H. · · 2021 · cited 1789× · PMID 34194012 · DOI 10.1038/s41573-021-00233-1
Mitochondrial dysfunction: mechanisms and advances in therapy.
Zong Y, Li H, Liao P, Chen L, et al · · 2024 · cited 614× · PMID 38744846 · DOI 10.1038/s41392-024-01839-8
Mitochondrial diseases: from molecular mechanisms to therapeutic advances.
Wen H, Deng H, Li B, Chen J, et al · · 2025 · cited 111× · PMID 39788934 · DOI 10.1038/s41392-024-02044-3
Pharmacological advances in mitochondrial therapy.
Singh A, Faccenda D, Campanella M. · · 2021 · cited 88× · PMID 33647769 · DOI 10.1016/j.ebiom.2021.103244
Oxidative Stress, Mitochondrial Dysfunction, and Neuroprotection of Polyphenols with Respect to Resveratrol in Parkinson's Disease.
Kung HC, Lin KJ, Kung CT, Lin TK. · · 2021 · cited 85× · PMID 34440122 · DOI 10.3390/biomedicines9080918
Human Sirtuin Regulators: The "Success" Stories.
Curry AM, White DS, Donu D, Cen Y. · · 2021 · cited 64× · PMID 34744791 · DOI 10.3389/fphys.2021.752117
Targeting NLRP3 Inflammasome With Nrf2 Inducers in Central Nervous System Disorders.
Tastan B, Arioz BI, Genc S. · · 2022 · cited 56× · PMID 35418995 · DOI 10.3389/fimmu.2022.865772
Transcriptional activation of antioxidant gene expression by Nrf2 protects against mitochondrial dysfunction and neuronal death associated with acute and chronic neurodegeneration.
Goodfellow MJ, Borcar A, Proctor JL, Greco T, et al · · 2020 · cited 53× · PMID 32061629 · DOI 10.1016/j.expneurol.2020.113247

Verify or expand the search:

Other trials of Resveratrol

Trials testing the same drug.

NCT06250283 — Resveratrol for the Prevention of Bone Loss in Postmenopausal Women · NA · completed
NCT05808387 — The Effects of Resveratrol on Sirtuins and Apoptosis Biomarkers · NA · recruiting
NCT06131918 — Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy · Phase 2 · completed
NCT05653895 — Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS · NA · completed
NCT05410093 — Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency · NA · unknown

Other recruiting trials for Friedreich Ataxia

Currently open trials in the same condition.

NCT06628687 — A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it Duri · recruiting
NCT07508631 — Friedreich Ataxia Nerve Ultrasund · recruiting
NCT06953583 — A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich' · Phase 3 · recruiting
NCT06623890 — A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who · recruiting
NCT06054893 — A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participa · Phase 1 · recruiting

Other Murdoch Childrens Research Institute trials

Trials by the same sponsor.

NCT07251790 — Optimising Breathing Support at Extubation in Very Preterm Infants: A Clinical Study · NA · not yet recruiting
NCT07136584 — SOS for Caregiver Wellbeing · NA · recruiting
NCT06686446 — Allergic Rhinitis Improvement Through Strategic Education: The ARISE Trial · NA · terminated
NCT06992141 — A Strep Throat Controlled Human Infection Trial in Healthy Adults · EARLY_PHASE1 · completed
NCT06186141 — Nausea and Vomiting in Postoperative Paediatric Patients With Patient-Controlled Analgesia (PCA): Morphine vs Oxycodone · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03933163 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Murdoch Childrens Research Institute
Last refreshed: 22 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03933163.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing